Organovo Holdings, Inc. (ONVO) - NYSEMKT
  • Fri, Jun. 10, 6:25 AM
    • Organovo Holdings (ONVO) FQ4 results: Revenues: $0.5M (+66.7%); R&D Expense: $4.5M (+25.0%); SG&A: $4.4M (-4.3%); Net Loss: ($8.4M) (-7.7%); Loss Per Share : ($0.09) (+10.0%).
    • FY2016 results: Revenues: $1.5M (+150.0%); R&D Expense: $18M (+39.5%); SG&A: $22.1M (+23.5%); Net Loss: ($38.6M) (-28.2%); Loss Per Share: ($0.43) (-13.2%); Quick Assets: $62.1M (+24.0%); CF Ops: ($29.4M) (-50.0%).
    • FY2017 Guidance: Total Revenue: $4M - 6M; Net Cash Utilization: $32.5M - 36.5M.
    | Fri, Jun. 10, 6:25 AM | 2 Comments
  • Thu, Jun. 9, 4:10 PM
    • Organovo Holdings (NYSEMKT:ONVO): FQ4 EPS of -$0.09 beats by $0.02.
    • Revenue of $0.55M (+103.7% Y/Y) beats by $0.25M.
    • Press Release
    | Thu, Jun. 9, 4:10 PM
  • Mon, Feb. 8, 5:01 PM
    • Despite its bullish prognostications about $100M+ revenue potential, micro cap Organovo (NYSEMKT:ONVO) continues to struggle to grow sales. Its top line for fiscal Q3 was only $0.3M. It is pinning its hopes on its exVive3D Human Liver Tissue and service, launched in November. It asserts that the liver assay alone will generate tens of millions in revenue. Exactly when is uncertain.
    • Commercial contracting for its kidney tissue product should commence in Q3.
    • Its fiscal 2016 outlook for revenue from previously reported contract bookings has been lowered to $0.7M - 0.9M from $1.2M - 1.4M. Net cash utilization should be $32M - 34M. As of December 31, the company's quick assets totaled $70M.
    • Previously: Organovo Holdings EPS in-line, misses on revenue (Feb. 8)
    | Mon, Feb. 8, 5:01 PM | 4 Comments
  • Mon, Feb. 8, 4:20 PM
    • Organovo Holdings (NYSEMKT:ONVO): FQ3 EPS of -$0.11 in-line.
    • Revenue of $0.33M (+106.3% Y/Y) misses by $0.11M.
    | Mon, Feb. 8, 4:20 PM
  • Nov. 10, 2015, 10:52 AM
    • Organovo Holdings (ONVO -6.5%) FQ2 results: Revenues: $0.3M (+500.0%); R&D Expense: $4.7M (+46.9%); SG&A: $6.8M (+17.2%); Net Loss: ($11.3M) (-27.0%); Loss Per Share: ($0.12) (-9.1%); Quick Assets: $76.9M (+53.5%).
    • 2016 Guidance: Total Revenue Recognized From Contract Bookings: $1.2M - 1.4M; Net Cash Utilization: $32M - 36M.
    | Nov. 10, 2015, 10:52 AM | 8 Comments
  • Nov. 9, 2015, 4:18 PM
    • Organovo Holdings (NYSEMKT:ONVO): FQ2 EPS of -$0.12 misses by $0.02.
    • Revenue of $0.3M in-line.
    | Nov. 9, 2015, 4:18 PM | 3 Comments
  • Aug. 11, 2015, 8:18 AM
    • Regenerative medicine firm Organovo (NYSEMKT:ONVO) slumps 19% in premarket trading on mediocre volume in response to its release of fiscal Q1 results after the close yesterday.
    • Although the company stated that contract bookings for its exVive3D Human Liver Tissue were ~$2M, recorded revenues were only ~$300K, far below the projected "tens of millions" eventual run rate that management believes is achievable.
    • Previously: Organovo says liver tissue will be $100M business (March 13)
    | Aug. 11, 2015, 8:18 AM | 11 Comments
  • Aug. 11, 2015, 8:15 AM
    • Organovo Holdings (ONVO +17.6%) FQ1 results: Revenues: $0.3M (+200.0%); R&D Expense: $4.1M (+46.4%); SG&A: $4.6M (+24.3%); Net Loss: ($8.5M) (-32.8%); Loss Per Share: ($0.10) (-25.0%); Quick Assets: $86M (+71.7%).
    • No guidance given.
    | Aug. 11, 2015, 8:15 AM | 1 Comment
  • Aug. 10, 2015, 4:50 PM
    • Organovo Holdings (NYSEMKT:ONVO): FQ1 EPS of -$0.10 misses by $0.01.
    • Revenue of $0.31M (+210.0% Y/Y) misses by $0.12M.
    | Aug. 10, 2015, 4:50 PM | 10 Comments
  • Jun. 9, 2015, 4:41 PM
    • Organovo (NYSEMKT:ONVO) fiscal 2015 results ($M): Total Revenues: 0.6 (+50.7%); Product & Service Revenue: 0.3 (999%); Operating Expenses: 30.9 (+47.1%); Net Loss: (30.1) (-16.4%); Quick Assets: 50.1 (+3.9%); CF Ops: (19.6) (-26.0%).
    • ExVive3D Human Liver Tissue sales in fiscal 2015: $0.29M. Bookings from April 1, 2014 to June 9, 2015: $1.94M.
    | Jun. 9, 2015, 4:41 PM | 9 Comments
  • Jun. 9, 2015, 4:23 PM
    • Organovo Holdings (NYSEMKT:ONVO): FY15 EPS of -$0.38 vs. -$0.35 in FY14
    • Revenue of $0.57M (+50.0% Y/Y)
    | Jun. 9, 2015, 4:23 PM
  • Feb. 9, 2015, 8:41 AM
    • Organovo Holdings (NYSEMKT:ONVO): FQ3 EPS of -$0.09 in-line.
    • Revenue of $0.15M (+7.1% Y/Y) in-line.
    | Feb. 9, 2015, 8:41 AM
  • Nov. 10, 2014, 8:22 AM
    • Organovo Holdings (NYSEMKT:ONVO): FQ2 EPS of -$0.11
    • Revenue of $0.05M (+150.0% Y/Y)
    | Nov. 10, 2014, 8:22 AM
  • Aug. 12, 2014, 8:15 AM
    • Organovo Holdings (NYSEMKT:ONVO): FQ1 EPS of -$0.08.
    • Revenue of $0.1M (flat Y/Y).
    • Shares -3.94% PM.
    | Aug. 12, 2014, 8:15 AM
  • Aug. 11, 2014, 12:55 PM
    • Organovo (ONVO +2.2%) fiscal Q1 results: Revenues: $99K (-6.6%); Net Loss: ($6.4M) (-70.6%); Loss Per Share: ($0.08) (-33.3%); Quick Assets: $44.9M (-6.8%); Cash Burn: ($3.4M) (-26.4%).
    • No financial guidance given.
    | Aug. 11, 2014, 12:55 PM | 1 Comment
Company Description
Organovo Holdings, Inc. is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can... More
Sector: Healthcare
Industry: Medical Laboratories & Research
Country: United States